Uncategorized

Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi

Published

on

Oruka Therapeutics’ Phase 2 psoriasis data could mean there’s a future challenger to megablockbuster Skyrizi.

The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug saw their skin plaques …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version